Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci175233 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Yifan Lin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China. Hauptthemen laut MEDLINE: Immunoglobulin A, SARS-CoV-2, COVID-19 Vaccines, Antibodies, Viral. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Emergency Key Program of Guangzhou Laboratory, National Science Fund for Distinguished Young Scholars, R&D Program of Guangzhou Laboratory.
Abstract (Originalsprache)
The persistent emergence of COVID-19 variants and recurrent waves of infection worldwide underscores the urgent need for vaccines that effectively reduce viral transmission and prevent infections. Current intramuscular (IM) COVID-19 vaccines inadequately protect the upper respiratory mucosa. In response, we have developed a nonadjuvanted, IFN-armed SARS-CoV-2 fusion protein vaccine with IM priming and intranasal (IN) boost sequential immunization. Our study showed that this sequential vaccination strategy of the IM+IN significantly enhanced both upper respiratory and systemic antiviral immunity in a mouse model, characterized by the rapid increase in systemic and mucosal T and B cell responses, particularly the mucosal IgA antibody response. The IN boost triggered a swift secondary immune response, rapidly inducing antigen-specific IgA + B cells. Further B cell receptor–seq (BCR-seq) analysis indicated that these IgA + B cells primarily arose through direct class switching from preexisting IgG + B cells in draining lymph nodes. Notably, our clinical studies revealed that the IN boost after IM vaccination elicited a robust systemic IgA antibody response in humans, as measured in serum. Thus, we believe that our cytokine-armed protein vaccine presents a promising strategy for inducing rapid and potent mucosal protection against respiratory viral infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China.
- Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
- Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Sh…
- Guangzhou Laboratory, Guangzhou International Bio-Island, Guangzhou, China.
- State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou…
- Changping Laboratory, Beijing, China.
Förderung
- Emergency Key Program of Guangzhou Laboratory
- National Science Fund for Distinguished Young Scholars
- R&D Program of Guangzhou Laboratory
- Shenzhen Science and Technology Program
- National Science Fund of China
Zitieren
APA
Lin, Y., Liao, X., Cao, X., Zhang, Z., Wang, X., He, X., Liao, H., Ju, B., Qi, F., Xu, H., Ren, Z., Wang, Y., Hu, Z., Yang, J., Fu, Y. X., Zhao, J., Zhang, Z., & Peng, H. (2025). Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2. Journal of Clinical Investigation. https://doi.org/10.1172/jci175233
Vancouver
Lin Y, Liao X, Cao X, Zhang Z, Wang X, He X, et al. Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2. Journal of Clinical Investigation. 2025. doi:10.1172/jci175233
BibTeX
@article{Lin2025,
author = {Lin, Yifan and Liao, Xuejiao and Cao, Xuezhi and Zhang, Zhaoyong and Wang, Xiuye and He, Xiaomeng and Liao, Huiping and Ju, Bin and Qi, Furong and Xu, Hairong and Ren, Zhenhua and Wang, Yanqun and Hu, Zhenxiang and Yang, Jiaming and Fu, Yang-Xin and Zhao, Jincun and Zhang, Zheng and Peng, Hua},
title = {Sequential intranasal booster triggers class switching from intramuscularly primed IgG to mucosal IgA against SARS-CoV-2},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci175233}
}
EUVIMED